New drug combo aims to cut nausea in weight loss treatments

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female at birth. * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 27.0 kilograms per square meter (kg/m\^2) and 39.9 kg/m\^2 (both inclusive) at screening. * Overweight should be due to excess adipose tissue, as judged by the investigator. * Considered eligible with suitable veins for cannulation or repeated venepuncture, as judged by the investigator. * No clinically significant findings during medical history, physical examination, vital signs, electrocardiogram or clinical laboratory tests at the screening visit, as assessed by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method. * Current participation (i.e., dosing) in any other interventional clinical study within 90 days before screening. * Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening, including incretin-based treatment(s). * Previous or planned (during the study period) obesity treatment with surgery. However, the following are allowed: 1. Liposuction and/or abdominoplasty, if performed greater than symbol (\>) 1 year before screening. 2. Adjustable gastric banding, if the band has been removed \> 1 year before screening. 3. Intragastric balloon, if the balloon has been removed \> 1 year before screening. 4. Duodenal-jejunal bypass liner (e.g., Endobarrier), if the sleeve has been removed \> 1 year before screening.